Aquestive Therapeutics Inc (AQST)

$4.18

-0.05

(-1.18%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $4.10
    $4.27
    $4.18
    downward going graph

    1.91%

    Downside

    Day's Volatility :3.98%

    Upside

    2.11%

    downward going graph
  • $1.25
    $6.23
    $4.18
    downward going graph

    70.06%

    Downside

    52 Weeks Volatility :79.91%

    Upside

    32.91%

    downward going graph

Returns

PeriodAquestive Therapeutics IncIndex (Russel 2000)
3 Months
52.0%
0.0%
6 Months
-26.41%
0.0%
1 Year
164.56%
0.0%
3 Years
-7.11%
-22.3%

Highlights

Market Capitalization
385.6M
Book Value
- $0.39
Earnings Per Share (EPS)
-0.36
Wall Street Target Price
8.81
Profit Margin
-44.07%
Operating Margin TTM
0.27%
Return On Assets TTM
-10.88%
Return On Equity TTM
0.0%
Revenue TTM
58.4M
Revenue Per Share TTM
0.79
Quarterly Revenue Growth YOY
51.800000000000004%
Gross Profit TTM
28.3M
EBITDA
-14.0M
Diluted Eps TTM
-0.36
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.44
EPS Estimate Next Year
-0.49
EPS Estimate Current Quarter
-0.12
EPS Estimate Next Quarter
-0.12

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Aquestive Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
12
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 110.77%

Current $4.18
Target $8.81

Company Financials

FY18Y/Y Change
Revenue
67.4M
↑ 0.77%
Net Income
-61.4M
↑ 586.3%
Net Profit Margin
-91.02%
↓ 77.66%
FY19Y/Y Change
Revenue
52.6M
↓ 21.98%
Net Income
-72.7M
↑ 18.38%
Net Profit Margin
-138.11%
↓ 47.09%
FY20Y/Y Change
Revenue
45.8M
↓ 12.85%
Net Income
-65.4M
↓ 10.04%
Net Profit Margin
-142.56%
↓ 4.45%
FY21Y/Y Change
Revenue
50.8M
↑ 10.87%
Net Income
-90.0M
↑ 37.75%
Net Profit Margin
-177.12%
↓ 34.56%
FY22Y/Y Change
Revenue
47.7M
↓ 6.2%
Net Income
-60.2M
↓ 33.14%
Net Profit Margin
-126.26%
↑ 50.86%
FY23Y/Y Change
Revenue
50.6M
↑ 6.09%
Net Income
-7.9M
↓ 86.93%
Net Profit Margin
-15.56%
↑ 110.7%
Q1 FY23Q/Q Change
Revenue
11.1M
↑ 4.23%
Net Income
19.3M
↓ 206.38%
Net Profit Margin
173.4%
↑ 343.3%
Q2 FY23Q/Q Change
Revenue
13.2M
↑ 18.92%
Net Income
-5.8M
↓ 130.0%
Net Profit Margin
-43.74%
↓ 217.14%
Q3 FY23Q/Q Change
Revenue
13.0M
↓ 1.8%
Net Income
-2.0M
↓ 64.87%
Net Profit Margin
-15.65%
↑ 28.09%
Q4 FY23Q/Q Change
Revenue
13.2M
↑ 1.57%
Net Income
-8.1M
↑ 298.57%
Net Profit Margin
-61.42%
↓ 45.77%
Q1 FY24Q/Q Change
Revenue
12.1M
↓ 8.73%
Net Income
-12.8M
↑ 58.16%
Net Profit Margin
-106.43%
↓ 45.01%
Q2 FY24Q/Q Change
Revenue
20.1M
↑ 66.76%
Net Income
-2.7M
↓ 78.6%
Net Profit Margin
-13.66%
↑ 92.77%
FY18Y/Y Change
Total Assets
86.9M
↑ 101.44%
Total Liabilities
76.8M
↑ 10.29%
FY19Y/Y Change
Total Assets
78.5M
↓ 9.64%
Total Liabilities
84.6M
↑ 10.2%
FY20Y/Y Change
Total Assets
62.9M
↓ 19.87%
Total Liabilities
111.4M
↑ 31.65%
FY21Y/Y Change
Total Assets
62.0M
↓ 1.42%
Total Liabilities
144.1M
↑ 29.4%
FY22Y/Y Change
Total Assets
55.7M
↓ 10.19%
Total Liabilities
174.2M
↑ 20.89%
FY23Y/Y Change
Total Assets
57.4M
↑ 3.13%
Total Liabilities
163.9M
↓ 5.93%
Q1 FY23Q/Q Change
Total Assets
61.3M
↑ 10.08%
Total Liabilities
170.5M
↓ 2.13%
Q2 FY23Q/Q Change
Total Assets
57.0M
↓ 7.0%
Total Liabilities
163.6M
↓ 4.03%
Q3 FY23Q/Q Change
Total Assets
59.4M
↑ 4.31%
Total Liabilities
162.4M
↓ 0.78%
Q4 FY23Q/Q Change
Total Assets
57.4M
↓ 3.41%
Total Liabilities
163.9M
↑ 0.94%
Q1 FY24Q/Q Change
Total Assets
129.5M
↑ 125.58%
Total Liabilities
165.8M
↑ 1.17%
Q2 FY24Q/Q Change
Total Assets
117.6M
↓ 9.2%
Total Liabilities
153.1M
↓ 7.68%
FY18Y/Y Change
Operating Cash Flow
-13.0M
↓ 323.06%
Investing Cash Flow
-1.8M
↓ 11.8%
Financing Cash Flow
58.0M
↑ 1214.79%
FY19Y/Y Change
Operating Cash Flow
-60.2M
↑ 363.47%
Investing Cash Flow
-663.0K
↓ 63.65%
Financing Cash Flow
49.6M
↓ 14.53%
FY20Y/Y Change
Operating Cash Flow
-45.5M
↓ 24.5%
Investing Cash Flow
-517.0K
↓ 22.02%
Financing Cash Flow
28.5M
↓ 42.63%
FY21Y/Y Change
Operating Cash Flow
-33.0M
↓ 27.45%
Investing Cash Flow
-913.0K
↑ 76.6%
Financing Cash Flow
30.1M
↑ 5.81%
Q1 FY23Q/Q Change
Operating Cash Flow
8.8M
↑ 4.38%
Investing Cash Flow
-2.0K
↑ 0.0%
Financing Cash Flow
-9.2M
↓ 4612.25%
Q2 FY23Q/Q Change
Operating Cash Flow
-7.9M
↓ 189.69%
Investing Cash Flow
-826.0K
↑ 41200.0%
Financing Cash Flow
4.3M
↓ 146.57%

Technicals Summary

Sell

Neutral

Buy

Aquestive Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aquestive Therapeutics Inc
Aquestive Therapeutics Inc
21.87%
-26.41%
164.56%
-7.11%
24.4%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-16.62%
-11.2%
10.78%
28.21%
20.17%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
7.49%
20.82%
28.48%
39.41%
39.41%
Zoetis Inc.
Zoetis Inc.
2.41%
4.25%
0.77%
-8.94%
49.4%
Viatris Inc.
Viatris Inc.
-0.79%
-8.6%
12.7%
-23.12%
-31.03%
Catalent, Inc.
Catalent, Inc.
0.82%
6.48%
22.57%
-57.47%
16.16%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aquestive Therapeutics Inc
Aquestive Therapeutics Inc
NA
NA
NA
-0.44
0.0
-0.11
NA
-0.39
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
36.53
36.53
0.27
4.57
0.16
0.12
NA
24.87
Haleon Plc Spon Ads
Haleon Plc Spon Ads
33.32
33.32
1.47
0.39
0.07
0.04
0.02
1.82
Zoetis Inc.
Zoetis Inc.
36.6
36.6
2.61
5.82
0.49
0.14
0.01
10.94
Viatris Inc.
Viatris Inc.
224.4
NA
0.07
2.68
-0.03
0.03
0.04
16.36
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.87
0.2
-0.25
0.0
NA
19.91
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aquestive Therapeutics Inc
Aquestive Therapeutics Inc
Buy
$385.6M
24.4%
NA
-44.07%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$12.2B
20.17%
36.53
16.0%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$47.1B
39.41%
33.32
9.66%
Zoetis Inc.
Zoetis Inc.
Buy
$85.7B
49.4%
36.6
26.29%
Viatris Inc.
Viatris Inc.
Hold
$13.5B
-31.03%
224.4
-4.24%
Catalent, Inc.
Catalent, Inc.
Hold
$10.9B
16.16%
211.02
-23.81%

Insights on Aquestive Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 12.05M → 20.09M (in $), with an average increase of 40.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -12.82M → -2.74M (in $), with an average increase of 367.3% per quarter

Institutional Holdings

  • Bratton Capital Management, L.P.

    10.77%

  • VR Adviser, LLC

    6.10%

  • BlackRock Inc

    5.99%

  • Vanguard Group Inc

    4.64%

  • Franklin Resources Inc

    3.13%

  • Renaissance Technologies Corp

    1.51%

Company Information

aquestive therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people’s lives. our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. our initial focus, supported by our current approved products and late stage pipeline, is to address immediate cns challenges.

Organization
Aquestive Therapeutics Inc
Employees
135
CEO
Mr. Daniel Barber
Industry
Health Technology

Discover More

FAQs